Consensus Medpace Holdings, Inc.

Stocks

MEDP

US58506Q1094

Biotechnology & Medical Research

Market Closed - Nasdaq 16:00:00 2026-10-19 EDT			5-day change	1st Jan Change
619.66 ^USD	+0.19%		-0.06%	+10.33%

09-21	Medpace Holdings Insider Sold Shares Worth $6,749,952, According to a Recent SEC Filing	MT
09-09	PriorNilsson Evolve Global rose 0.49 percent in August, increased exposure to Kitron and Scanfil	FW

Evolution of the Average Target: Medpace Holdings, Inc.

Evolution of the Target Price: Medpace Holdings, Inc.

Changes in Analyst Recommendations: Medpace Holdings, Inc.

0c9035ea2e7ea8ce9de4e9730d70a5fb.f3hbQ4hM6W2xsBy4tyz5mvvN2zlHAwqysvRZ8PGa-c0.GDEZNvENiwWIhV328U_MwMnglXoFXHCDh7Mhnr7Vy7wcLDAl5CiIOPD0ew~95da5ba89dd97aaeeb2fd7e547b48a60

Analysts' recommendations: Medpace Holdings, Inc.

09-30	UBS Upgrades Medpace Holdings to Neutral From Sell, Adjusts Price Target to $673 From $405	MT
08-21	Analyst recommendations: Equifax, Medpace Holdings, Applied Materials, PayPal, Moderna…
07-28	Analyst recommendations: Intuit, AMD, Fortinet, Globe Life…
07-24	Medpace's Bookings Recovery, Normalization of Cancellations Support Growth, RBC Says	MT
07-24	Truist Raises Price Target on Medpace Holdings to $609 From $462, Keeps Hold Rating	MT
07-24	RBC Raises Price Target on Medpace Holdings to $692 From $484, Keeps Outperform Rating	MT
07-24	Analyst recommendations: Netflix, Tapestry, Tesla, AMD, Intel…
07-23	Medpace jumps 15%, order rebound eases fears
07-23	Deutsche Bank Adjusts Medpace Price Target to $535 From $480, Maintains Hold Rating	MT
07-08	Medpace Shares Fall After Baird Downgrade	MT
07-08	Baird Downgrades Medpace to Neutral From Outperform, Adjusts PT to $547 From $477	MT
07-07	Medpace Shares Fall After Jefferies Downgrade	MT
07-07	Jefferies Downgrades Medpace Holdings to Hold From Buy, Adjusts Price Target to $515 From $490	MT
07-07	Analyst recommendations: Ferguson, Medpace, Biogen, Crowdstrike, Take-Two…
04-24	Truist Adjusts Price Target on Medpace to $462 From $539, Maintains Hold Rating	MT
04-24	RBC Lowers Price Target on Medpace Holdings to $484 From $522, Keeps Outperform Rating	MT
04-23	Deutsche Bank Cuts Price Target on Medpace Holdings to $425 From $480, Keeps Hold Rating	MT
03-03	Medpace is Differentiated as Most Efficient Contract Research Organization, RBC Says	MT
03-03	RBC Initiates Medpace Holdings at Outperform With $522 Price Target	MT
02-18	Medpace Shares Rise After TD Cowen Upgrade	MT
02-18	TD Cowen Upgrades Medpace Holdings to Hold From Sell, Adjusts Price Target to $419 From $462	MT
02-13	Medpace Shares Rise After Jefferies Upgrade	MT
02-13	Jefferies Upgrades Medpace to Buy From Hold, $560 Price Target	MT
02-11	Deutsche Bank Adjusts Medpace Price Target to $480 From $600, Maintains Hold Rating	MT
02-11	Truist Securities Adjusts Price Target on Medpace to $539 From $555, Maintains Hold Rating	MT

More recommendations

Other Biotechnology & Medical Research

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Consensus	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
	MEDPACE HOLDINGS, INC.					-3.65%
	WUXI APPTEC CO., LTD.					+32.97%
	LONZA GROUP AG					+14.74%
	ARGENX SE					+38.45%
	IQVIA HOLDINGS INC.					+12.07%
	BEONE MEDICINES AG					+18.26%
	REVOLUTION MEDICINES, INC.					+44.87%
	CELLTRION, INC.					+38.06%
	WUXI BIOLOGICS (CAYMAN) INC.					+24.78%
	GENMAB A/S					+8.87%
	Average					+22.94%
	Weighted average by Cap.					+25.41%